Institution statistics

SANOFI-AVENTIS RECHERCHE & DEVELOPPEMENT - France 

This institution has been merged with: SANOFIAVENTIS.

Ranking results:

Past rankings:
2018
Criterium:Position:
Overall Score:900-1000
Total Number of Projects:400-500
Networking Rank (Reputation):> 1000
2016
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):> 1000
2012
Criterium:Position:
Overall Score:900-1000
Total Project Funding per Partner:> 1000
Total Number of Projects:70
Total Project Funding:> 1000
Networking Rank (Reputation):> 1000
Networking Rank (Reputation):> 1000
Partner Constancy:46
Project Leadership Index:75
Diversity Index:60
2011
Criterium:Position:
Overall Score:> 1000
Networking Rank (Reputation):800-900
Ranking timeline:

European project participation (2010-01-01 - 2021-12-31 ):

Performance:

Funding:

Total funding allocated to projects this organisation participated or coordinated

Funding per Partner:

Since 2014 individual funding per partner. If data is not available at CORDIS: total funding / No of participants.

Projects:
Leadership:

Total number of projects: 19
As coordinator: 0
As participant: 19
Sole participant: 0
Coordinator / Participant Ratio: 0*

*Ratio includes only projects with > 2 partners

Summary:
Total project funding [€]:Projects [No]:
Year:coordinator*participant*per partner  as coordinatoras participant
2018 0 99.354.681 0 5
2017 0 36.861.590 412.423 5
2016 0 20.650.631 0 3
2013 0 8.197.401 985.539 2
2012 0 8.000.000 616.154 1
2011 0 15.625.805 1.097.986 2
2010 0 6.998.220 235.574 1
*n.b.: These numbers represent the total amount of funds allocated to projects this institution has participated in, not the funding allocated to this institution

Networking:

Partners:
Institution:Projects [No]:
ELI LILLY AND COMPANY LIMITED8
JANSSEN PHARMACEUTICA NV8
F HOFFMANNLA ROCHE7
NOVARTIS PHARMA7
PFIZER LIMITED7
BAYER AKTIENGESELLSCHAFT6
UCB BIOPHARMA6
ASTRAZENECA AB5
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT5
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER5
BOEHRINGER INGELHEIM PHARMA GMBH &CO KG4
CHARITE UNIVERSITAETSMEDIZIN BERLIN4
INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE4
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD4
THE UNIVERSITY OF LIVERPOOL4
UNIVERSITY COLLEGE LONDON4
AMGEN LIMITED3
ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE3
ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM3
EUROPEAN PATIENTS' FORUM3
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE3
KAROLINSKA INSTITUTE3
MERCK KOMMANDITGESELLSCHAFT AUF AKTIEN3
MERCK SHARP & DOHME CORP3
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE3
ORION OYJ3
SYNAPSE RESEARCH MANAGEMENT PARTNERS SL3
UNIVERSITAT WIEN3
UNIVERSITY OF NEWCASTLE UPON TYNE3
UPPSALA UNIVERSITET3
ABBVIE DEUTSCHLAND GMBH & CO KG2
ABBVIE INC2
ASTELLAS PHARMA EUROPE BV2
AXXAM2
CELGENE MANAGEMENT SARL2
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE2
DEGUSSA2
EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH2
EUROPEAN CANCER PATIENT COALITION2
EUROPEAN MOLECULAR BIOLOGY LABORATORY2
EURORDIS EUROPEAN ORGANISATION FOR RARE DISEASES ASSOCIATION2
FEDERATION EUROPEENNE D'ASSOCIATIONS ET D'INDUSTRIES PHARMACEUTIQUES2
FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E V2
FUNDACIO SANT JOAN DE DEU2
H LUNDBECK AS2
INSTITUT PASTEUR2
INTERNATIONAL ALLIANCE OF PATIENT'ORGANIZATIONS2
KATHOLIEKE UNIVERSITEIT LEUVEN2
KING'S COLLEGE LONDON2
NOVO NORDISK2
QUEEN MARY AND WESTFIELD COLLEGE UNIVERSITY OF LONDON2
STICHTING KATHOLIEKE UNIVERSITEIT2
TAKEDA DEVELOPMENT CENTRE EUROPE2
TARTU ULIKOOL2
THE ASSOCIATION OF THE BRITISH PHARMACEUTICAL INDUSTRY2
THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE2
UNIVERSITA DEGLI STUDI DEL PIEMONTE ORIENTALE AMEDEO AVOGADRO2
UNIVERSITAETSKLINIKUM HEIDELBERG2
UNIVERSITAIR MEDISCH CENTRUM UTRECHT2
UNIVERSITE CATHOLIQUE DE LOUVAIN2
UNIVERSITEIT LEIDEN2
UNIVERSITY COLLEGE CORK NATIONAL UNIVERSITY OF IRELAND CORK2
UNIVERSITY OF OSLO2
VERBAND FORSCHENDER ARZNEIMITTELHERSTELLER EV2
A N BAKH INSTITUTE OF BIOCHEMISTRY OF THE RUSSIAN ACADEMY OF SCIENCES1
ABBVIE1
ABO AKADEMI1
ACADEMISCH ZIEKENHUIS GRONINGEN1
ACTELION PHARMACEUTICALS1
ADVANCELL ADVANCED IN VITRO CELL TECHNOLOGIES1
AGENZIA ITALIANA DEL FARMACO1
ALERE TECHNOLOGIES1
ALEXION SERVICES EUROPE SPRL1
ALTIUS INSTITUTE FOR BIOMEDICAL SCIENCES1
ALZHEIMER EUROPE1
AMGEN1
ARISTOTLE UNIVERSITY THESSALONIKI1
ARLENDA1
ARSENALIT CENTRO VENETO RICERCAE INNOVAZIONE PER LA SANITA DIGITALE1
ARTTIC1
ASOCIACION NACIONAL EMPRESARIAL DE LA INDUSTRIA FARMACEUTICA1
ASSISTANCE PUBLIQUE HOPITAUX DE PARIS1
ASSOCIACAO PARA INVESTIGACAO E DESENVOLVIMENTO DA FACULDADE DE MEDICINA1
ASTRAZENECA INDIA PVT1
AZIENDA SANITARIA UNIVERSITARIA FRIULI CENTRALE1
AZIENDA SANITARIA UNIVERSITARIA INTEGRATA DI UDINE1
BAYER1
BAYER PHARMA1
BIOCOMPUTING PLATFORMS LTD OY1
BIOEMISSION TECHNOLOGY SOLUTIONS IKE1
CAMBRIDGE INNOVATION TECHNOLOGIES CONSULTING LIMITED1
CELLWORKS RESEARCH INDIA PRIVATE LIMITED1
CEMM FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN1
CENTRO DE NEUROCIENCIAS E BIOLOGIACELULAR ASSOCIACAO1
CERMAKOVA IVA1
CERTARA UK LIMITED1
COLLABORATIVE DRUG DISCOVERY INC CORPORATION1
COMMISSARIAT A L'ENERGIE ATOMIQUE1
CONCENTRIS RESEARCH MANAGEMENT1
CONSIGLIO NAZIONALE DELLE RICERCHE1
Constancy:

Total number of partners:399

Partner loyalty:
Frequent Partner: (> 2 projects): 130
Rare Partner: 269

Frequent / Rare Partner Ratio: 0.48

Diversity:

Categories:
Category:No:
BIOLOGICAL SCIENCES4
INDUSTRY AND TECHNOLOGY2
RTD HORIZONTAL TOPICS1

Project overview:

Start dateProjectacronymrolefundingpartners
2018-11-01European Health Data and Evidence Network EHDENparticipant14.105.75022
2018-07-01Research empowerment on solute carriers (ReSOLUTE) ReSOLUTEparticipant12.000.00014
2018-06-01The GetReal Initiative GetReal Initiativeparticipant1.750.00017
2018-05-01conect4children (COllaborative Network for European Clinical Trials For Children) c4cparticipant67.000.00048
2018-03-01Patients Active in Research and Dialogues for an Improved Generation of Medicines: Advancing meaningful patient engagement in the life cycle of medicines for better health outcomes. PARADIGMparticipant4.498.93134
2017-10-01European Quality In Preclinical Data EQIPDparticipant4.495.52330
2017-02-01Big Data for Better Outcomes, Policy Innovation and Healthcare System Transformation - Sofia ref.: 116055 DO-ITparticipant3.549.83336
2017-02-01Cardio Ultraefficient nanoParticles for Inhalation of Drug prOducts CUPIDOparticipant6.094.78113
2017-01-01Multiple manifestations of genetic and non-genetic factors in Multiple Sclerosis disentangled with a multi-omics approach to accelerate personalised medicine MultipleMSparticipant14.721.45322
2017-01-01Translational quantitative systems toxicology to improve the understanding of the safety of medicines - Sofia: 116030 TransQSTparticipant8.000.00023
2016-11-01Inflammation and AD: modulating microglia function focussing on TREM2 and CD33 - Sofia ref.: 115976 PHAGOparticipant8.838.00020
2016-10-01Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 PREFERparticipant6.000.00033
2016-01-01Imaging the Force of Cancer FORCEparticipant5.812.63116
2013-10-01Label Free Particle Sorting LAPASOparticipant4.228.4188
2013-01-01Infection biology training network: shaping the future of infectious diseases treatments INBIONETparticipant3.968.98310
2012-05-01New Oral Nanomedicines: Transporting Therapeutic Macromolecules across the Intestinal Barrier TRANS-INTparticipant8.000.00017
2011-11-01Novel nanoparticles for drug delivery to the skin NANODRUGparticipant3.752.7538
2011-02-01More Medicines for Tuberculosis MM4TBparticipant11.873.05225
2010-10-01Modern polymer-based catalysts and microflow conditions as key elements of innovations in fine chemical syntheses POLYCATparticipant6.998.22022
Data provision: © European Union; Source: CORDIS, http://cordis.europa.eu/ | This page is not provided by the European Commission see:Impressum